AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
aclarubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antineoplastics, daunorubicin derivatives | 80 | 57576-44-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.Aclarubicin is evaluated for the treatment of different conditions like acute myeloid leukemia, thyroid cancer, gastric cancer, lymphoma, small cell lung cancer. It is an inhibitor of topoisomerase II inhibitor being used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,KDR,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 38 | |||
| kinase-selectivity-class | MAP2K6,PDK1 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 150.14 | 80.23 | 38 | 439 | 53553 | 90574417 |
| Bone marrow failure | 105.73 | 80.23 | 26 | 451 | 32195 | 90595775 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 128.26 | 64.67 | 39 | 552 | 40422 | 42580322 |
| Bone marrow failure | 92.40 | 64.67 | 29 | 562 | 33064 | 42587680 |
| Thrombocytopenia | 69.83 | 64.67 | 39 | 552 | 190240 | 42430504 |
| Neutropenia | 65.42 | 64.67 | 38 | 553 | 199393 | 42421351 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 250.80 | 93.36 | 74 | 1053 | 94266 | 110493906 |
| Bone marrow failure | 196.39 | 93.36 | 55 | 1072 | 57793 | 110530379 |
| Thrombocytopenia | 120.34 | 93.36 | 62 | 1065 | 348823 | 110239349 |
| Neutropenia | 107.73 | 93.36 | 59 | 1068 | 374561 | 110213611 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01DB04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances |
| MeSH PA | D000276 | Adjuvants, Immunologic |
| MeSH PA | D000903 | Antibiotics, Antineoplastic |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50750 | EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
| CHEBI has role | CHEBI:76969 | bacterial metabolite |
Related Drugs by ATC class:
L01DB Anthracyclines and related substances 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute myeloid leukemia, disease | indication | 91861009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.01 | acidic |
| pKa2 | 9.34 | acidic |
| pKa3 | 8.65 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA topoisomerase 1 | Enzyme | INHIBITOR | KEGG DRUG | KEGG DRUG | |||||
| DNA topoisomerase II | Enzyme | INHIBITOR | KEGG DRUG | KEGG DRUG | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.15 | DRUG MATRIX | |||||
| 72 kDa type IV collagenase | Enzyme | IC50 | 5 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000168464 | NUI |
| D01911 | KEGG_DRUG |
| 239 | RXNORM |
| C0001143 | UMLSCUI |
| CHEBI:74619 | CHEBI |
| CHEMBL502620 | ChEMBL_ID |
| D015250 | MESH_DESCRIPTOR_UI |
| DB11617 | DRUGBANK_ID |
| C011157 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4945 | INN_ID |
| 74KXF8I502 | UNII |
| 451415 | PUBCHEM_CID |
| CHEMBL1697719 | ChEMBL_ID |
| 75443-99-1 | SECONDARY_CAS_RN |
| 003919 | NDDF |
| 003920 | NDDF |
| 326830005 | SNOMEDCT_US |
| 391713006 | SNOMEDCT_US |
| 391714000 | SNOMEDCT_US |
Pharmaceutical products:
None